Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting Pyk2 is a small interfering RNA designed to silence the expression of Proline-rich tyrosine kinase 2 (Pyk2), also known as Protein tyrosine kinase 2 beta (PTK2B). Pyk2 is a non-receptor tyrosine kinase that is activated by various stimuli, including the insulin-like growth factor receptor I (IGF-IR). In urothelial carcinoma (bladder cancer), Pyk2 is often overexpressed and plays a critical role in promoting cell motility and invasion. Silencing Pyk2 using siRNA approaches has been shown to inhibit IGF-I-dependent activation of the Akt and MAPK pathways, which are essential for the establishment of an invasive phenotype in cancer cells. This agent is primarily utilized as a research tool to investigate the role of Pyk2 in oncogenesis and to validate it as a potential therapeutic target in invasive bladder cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siRNA targeting Pyk2.